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Abstract
Background: A systemic inflammatory response is 
observed after cardiopulmonary resuscitation. We inves-
tigated two novel inflammatory markers, pentraxin 
3  (PTX3) and soluble suppression of tumorigenicity 
2  (sST2), in comparison with the classic high-sensitivity 
C-reactive protein (hsCRP), for prediction of early multi-
ple organ dysfunction syndrome (MODS), early death, and 
long-term outcome after out-of-hospital cardiac arrest.
Methods: PTX3, sST2, and hsCRP were assayed at ICU 
admission and 48  h later in 278 patients. MODS was 
defined as the 24  h non-neurological Sequential Organ 
Failure Assessment (SOFA) score  ≥ 12. Intensive care unit 
(ICU) death and 12-month Cerebral Performance Category 
(CPC) were evaluated.
Results: In total, 82% of patients survived to ICU discharge 
and 48% had favorable neurological outcome at 1 year (CPC 1 
or 2). At ICU admission, median plasma levels of hsCRP 
(2.8  mg/L) were normal, while levels of PTX3 (19.1 ng/mL) 
and sST2 (117 ng/mL) were markedly elevated. PTX3 and sST2 
were higher in patients who developed MODS (p < 0.0001). 
Admission levels of PTX3 and sST2 were also higher in 
patients who died in ICU and in those with an unfavorable 
12-month neurological outcome (p < 0.01). Admission levels 
of PTX3 and sST2 were independently associated with subse-
quent MODS [OR: 1.717 (1.221–2.414) and 1.340, (1.001–1.792), 
respectively] and with ICU death [OR: 1.536 (1.078–2.187) 
and 1.452 (1.064–1.981), respectively]. At 48 h, only sST2 and 
hsCRP were independently associated with ICU death.
Conclusions: Higher plasma levels of PTX3 and sST2, 
but not of hsCRP, at ICU admission were associated with 
higher risk of MODS and early death.
Keywords: cardiac arrest; pentraxin 3 (PTX3); ST2.
Introduction
Despite an initially successful return to spontaneous cir-
culation (ROSC), prognosis of cardiac arrest remains poor, 
with the majority of resuscitated patients dying early due to 
post-cardiac arrest syndrome [1]. Most prominent, together 
with myocardial failure and ischemic brain damage, is the 
systemic inflammation related to whole body ischemia 
and reperfusion and including plasma cytokine elevation 
with deregulated cytokine production, presence of endo-
toxin in plasma, coagulation abnormalities, and adrenal 
Brought to you by | EP Ipswich
Authenticated
Download Date | 10/9/15 12:13 PM
1848      Ristagno et al.: PTX3 and ST2 in cardiac arrest
dysfunction [2, 3]. Accordingly, this systemic inflammatory 
response observed after cardiopulmonary resuscitation 
(CPR) brings evident similarities with sepsis and septic 
shock, generally described as a “sepsis-like” syndrome 
[2]. Indeed, the role of inflammation in the progression 
towards worse circulatory shock, multiple organ dysfunc-
tion syndrome (MODS), and poor outcome of resuscitated 
patients is under research [1–3].
Thus, the importance of circulating markers in 
patients resuscitated from cardiac arrest for early prognos-
tic stratification is expanding towards markers of inflam-
mation [2–6]. Pentraxin 3 (PTX3) and soluble suppression 
of tumorigenicity 2 (sST2) are two novel markers that are 
emerging as new candidate indicators of inflammation, 
infection, and cardiovascular disease [7–13]. PTX3 is a pro-
totypic long pentraxin produced mainly by dendritic cells, 
macrophages, and endothelial cells in response to primary 
inflammatory stimuli, while ST2 is a member of the toll-
like/interleukin (IL)-1 receptor host defence/inflammation 
family, participating in inflammatory processes [9, 13].
Since the systemic inflammation following resusci-
tation from cardiac arrest includes leucocyte activation 
and endothelial injury, as well as innate and immune 
responses, important elevations in plasma levels of PTX3 
and ST2 might be expected [1, 2]. Thus, in the present 
study, we examined circulating levels of PTX3 and sST2, 
in a large population of patients resuscitated from out-of-
hospital cardiac arrest. The classic short pentraxin high-
sensitivity C-reactive protein (hsCRP) has been used as 
a benchmark biomarker of systemic inflammation [14]. 
In response to primary inflammatory stimuli CRP is pro-
duced mainly by the liver, while PTX3 and sST2 by diverse 
cell types, so we hypothesized that PTX3 and sST2 would 
be acute-phase markers more closely related than hsCRP 
to the severity of post-cardiac arrest syndrome and there-
fore would be better prognostic indicators in this context.
Materials and methods
Study design, setting and selection of participants
The study was an observational cohort study, in which plasma levels 
of inflammatory biomarkers, hsCRP, PTX3, and sST2, were assessed in 
adult patients resuscitated from out-of-hospital cardiac arrest. Patients 
included in the present study were part of FINNRESUSCI, a prospec-
tive observational cohort study conducted at 21 hospitals in Finland 
between 1 March, 2010 and 28 February, 2011 [15]. The study was 
approved by the Ethics Committee of the Helsinki and Uusimaa Hospi-
tal District (FINNRESUSCI TUTKIMUS §10, 20.1.201), in addition to local 
ethics approvals by Päijät-Häme, Etelä-Karala, Satakunta, Kymenlaakso 
Central Hospitals and Tampere and Turku University Central Hospitals. 
The study complied with the World Medical Association Declaration of 
Helsinki. Informed consent from the patient’s next of kin was obtained 
for data collection and blood sampling. All cardiac arrest patients in 
whom blood samples were obtained at intensive care unit (ICU) admis-
sion were included in the study. Details on post-resuscitation care are 
reported in the original publication of the  FINNRESUSCI study [15].
Data collection, processing and outcomes
The participating hospitals were a part of the Finnish Intensive Care 
Consortium (FICC) and used the same electronic data management 
system and data validation software (Web Validator, Tieto, Helsinki, 
Finland). Data on study patients were prospectively collected using 
an Internet-based case report forms. Pre-hospital data were collected 
by the paramedics in accordance with the Utstein Guidelines and 
included: whether the arrest was witnessed or not; the administration 
of bystander initiated life support; the time from call to the dispatch 
centre and ROSC; and the use of adrenaline. In-hospital care data were 
collected electronically and comprised the use of vasopressors and ther-
apeutic hypothermia, the Sequential Organ Failure Assessment (SOFA) 
score, Acute Physiology and Chronic Health Evaluation (APACHE) II 
score, and ICU mortality. The condition of MODS was defined as a SOFA 
score  ≥ 12 [16]. More specifically, the entire SOFA score was used and it 
was reported as worst value during the first 24 h of ICU care. A special-
ist in neurology blinded to management in the ICU contacted patients 
discharged from the hospital by phone 1 year after cardiac arrest and 
determined neurological outcome according to the Pittsburgh Cerebral 
Performance Categories (CPC). We defined 12-month favorable out-
come as CPC 1-2 (absent, mild or moderate neurological disability), and 
12-month unfavorable outcome as CPC 3-5 (severe neurological disabil-
ity, persistent vegetative state or death) [17].
Methods of measurement
Plasma levels of inflammatory biomarkers, hsCRP, PTX3, and sST2, at 
ICU admission and 48 h later, were measured blinded to case identity. 
Blood samples were collected into ethylenediaminetetra-acetic acid 
tubes, centrifuged and plasma stored at –70 °C. Plasma samples were 
collected in each participating center and then shipped in dry ice to 
a central repository where they were stored at –70 °C. Upon analysis, 
samples were thawed and divided into aliquots. The biomarkers were 
assayed in two different laboratories, one for hsCRP and PTX3, and 
the other for sST2. HsCRP levels were assayed using the latex immu-
noassay CRP Vario-High Sensitivity Method, by instrument Ci16200 
Architect (Abbott Diagnostics USA) [3]. PTX3 levels were assayed with 
a non-commercial ELISA based on the monoclonal antibody MNB10 
and rabbit anti-serum [7]. sST2 levels were assayed using a commer-
cial enzyme immunoassay (Presage ST2, Critical Diagnostics) after 
dilution of samples by 1/150.
Statistical analysis
Categorical variables are presented as proportions and continuous 
variables as mean with SEM or median with interquartile range (IQR).
Baseline characteristics by outcomes occurrence were investi-
gated with the χ2-test for categorical variables; continuous variables 
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were compared by analysis of variance or by the non-parametric 
Kruskal-Wallis test for continuous non-normally distributed data. 
Multivariable linear regression was used to identify the independent 
factors at resuscitation influencing inflammatory biomarkers lev-
els at ICU admission and 48 h later. Results of linear regression are 
reported in terms of β coefficients with 95% confidence interval (CI) 
and p-Values. Multivariable logistic regression was used to identify 
factors that were predictors of MODS, ICU mortality, and 12-month 
unfavorable outcome. All variables associated with the outcome in 
the univariate analysis (p < 0.05) were included in the multivariable 
model. Odds ratios (OR) with the corresponding 95% CI were calcu-
lated and p-Values were considered statistically significant if they 
were  < 0.05. Prognostic accuracy of inflammatory biomarkers was 
evaluated by receiver operating characteristic curve (ROC) analyses 
and compared with Delong test [18]. All statistical analyses were per-
formed with SAS software, version 9.2 (SAS Institute, Inc., Cary, NC, 
USA).
Results
The FINNIRESUSCI study included 548 patients [15]. 
Among these, informed consent for blood sampling was 
obtained in 278 patients, and they were all included in 
the study. However, for some patients only the 48 h blood 
sample was available due to delayed consent. Eighty-two 
percent of these 278 patients survived to ICU discharge 
and 48% had favorable neurological outcome (CPC 1 or 2) 
at 12 months (Table 1).
Baseline characteristics and factors influencing ICU 
survival and 12-month outcome are shown in Table 1. 
Pre-hospital factors univariately associated with ICU sur-
vival were a shockable rhythm, no use of adrenaline, a 
shorter time to ROSC, and the use of therapeutic hypother-
mia, while those associated with long-term survival and 
Table 1: Baseline characteristics and clinical factors at resuscitation in all patients and between survivors and non-survivors and patients 
with favorable and unfavorable outcome at 12 months.
Whole 
population
(n = 278)
ICU survival 12-month survivala 12-month outcomea
Yes 
(n = 229)
No 
(n = 49)
Yes 
(n = 143)
No 
(n = 133)
Favorable 
(n = 133)
Unfavorable 
(n = 143)
Age, mean (SD) 63±13 63±12 64±14 61±12b 65±13 60±12c 65±13
Sex (male), n (%) 229 (82) 189 (83) 40 (82) 117 (82) 111 (83) 109 (82) 119 (83)
Shockable rhythm, n (%) 180 (65) 163 (71)d 17 (35) 115 (80)b 64 (48) 108 (81)c 71 (50)
Witnessed cardiac arrest, n (%) 254 (91) 212 (93) 42 (86) 136 (95)e 116 (87) 128 (96)c 124 (87)
Bystander initiated BLS, n (%) 158 (57) 133 (58) 25 (51) 87 (61) 71 (53) 82 (62) 76 (53)
Adrenaline used, n (%) 186 (67) 141 (62)d 45 (92) 74 (52)b 111 (83) 67 (50)c 118 (83)
Time to ROSC in min, mean (SD) 21±11 20±11d 25±10 18±10b 24±11 18±10c 24±11
Therapeutic hypothermia, n (%) 202 (73) 173 (76)f 29 (59) 112 (78)e 89 (67) 104 (78) 97 (68)
BLS, basic life support; SD, standard deviation. aData on 12-month survival/outcome were missing for two patients; bp < 0.01 vs. 
12-month death; cp < 0.01 vs. unfavorable outcome at 12 months; dp < 0.01 vs. ICU death and ep < 0.05 vs. 12-month death and fp < 0.05 vs. 
ICU death.
favorable neurological outcome included also a younger 
age and a witnessed cardiac arrest (Table 1).
Inflammatory markers and factors related to 
resuscitation
Upper limits of normality for plasma hsCRP, PTX3, and 
sST2 in the general population are 3 mg/L [19], 4.76 ng/mL 
[20], and 45.6 ng/mL (manufacturer’s data from Presage 
ST2 assay, Critical Diagnostics), respectively.
In our patients, at ICU admission, median plasma levels 
of hsCRP were normal, 2.8 (1.2–9.8) mg/L, while levels of 
PTX3 and sST2 were already markedly elevated, 19.1 (9.2–
41.8) ng/mL and 117 (67–218) ng/mL, respectively. Levels of 
hsCRP and sST2 were significantly higher in patients with 
an initial non-shockable rhythm compared to those with a 
shockable rhythm, while levels of PTX3 were significantly 
higher in the case of longer time to ROSC (Table 2).
Each inflammatory marker significantly increased 
48 h later as shown in Figure 1. Forty-eight hour plasma 
levels of PTX3 were significantly higher in the instance of 
older age, shockable rhythm, and longer time to ROSC, 
while sST2 levels were significantly higher in the case of 
non-shockable rhythm and longer time to ROSC (Table 2). 
At 48 h after resuscitation, all the inflammatory markers 
were significantly higher in patients who were treated 
with therapeutic hypothermia.
By linear regression models, the common independent 
determinants of elevated levels of the three inflammatory 
markers assayed were: the presence of a non-shockable 
rhythm and the use of adrenaline, at ICU admission; and 
the APACHE II score, at 48 h (Table 3).
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Table 2: High-sensitivity C-reactive protein (hsCRP), pentraxin 3 (PTX3), and soluble suppression of tumorigenicity 2 (sST2) levels by age, 
cardiac arrest (CA) presenting rhythm, time to ROSC, and therapeutic hypothermia.
Variable n hsCRP, mg/L PTX3, ng/mL sST2, ng/mL
Admission levels
Age, year
  < 59 79 2.3 (1.4–5.1) 17.5 (8.7–39.9) 107 (66–202)
 59–68 86 2.4 (1.1–8.7) 20.3 (7.6–43.5) 117 (72–210)
  > 68 81 4.6 (1.5–11.7) 24.0 (12.4–44.7) 144 (69–240)
 p-Value 0.251 0.211 0.452
CA presenting rhythm
 Shockable 156 2.3 (1.2–5.4) 17.4 (8.7–36.2) 105 (60–189)
 Non-shockable 89 6.2 (1.9–29.5) 24.5 (11.2–60.3) 175 (95–373)
 p-Value  < 0.0001 0.054  < 0.0001
Time to ROSC, min
 1–15 83 3.0 (1.7–11.7) 14.1 (6.6–29.8) 102 (65–210)
 16–24 83 4.3 (1.5–14.6) 19.1 (8.2–48.2) 147 (66–277)
 25–57 80 1.9 (1.0–4.4) 24.9 (15.0–46.1) 123 (74–203)
 p-Value 0.005 0.002 0.287
48 h levels
Age, year
  < 59 75 115 (77–150) 37.1 (18.3–55.1) 299 (136–556)
 59–68 84 131 (93–165) 44.3 (21.0–79.3) 277 (176–461)
  > 68 68 131 (92–172) 50.1 (24.8–81.8) 275 (186–442)
 p-Value 0.373 0.038 0.988
CA presenting rhythm
 Shockable 162 124 (87–161) 47.6 (24.3–72.7) 256 (157–189)
 Non-shockable 65 124 (73–161) 33.2 (12.6–51.4) 353 (208–808)
 p-Value 0.742 0.004 0.001
Time to ROSC, min
 1–15 79 116 (74–147) 33.2 (16.8–62.6) 225 (118–392)
 16–24 74 133 (78–163) 42.1 (21.8–69.5) 277 (205–416)
 25–57 74 131 (97–169) 47.0 (25.9–93.5) 341 (189–597)
 p-Value 0.056 0.033 0.003
Therapeutic hypothermia
 Yes 180 131 (92–165) 47.3 (23.7–77.2) 298 (184–534)
 No 47 102 (56–143) 28.6 (16.8–45.7) 219 (97–381)
 p-Value 0.005 0.001 0.007
Data are reported as median and (IQR).
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Figure 1: Plasma levels of high-sensitivity C-reactive protein (hsCRP), pentraxin 3 (PTX3), and soluble suppression of tumorigenicity 2 
(sST2) at ICU admission (0 h) and 48 h later, and absolute Δ of changes during the 48 h (on the top). 
The number of patients is in italics. Plasma levels of the same inflammatory biomarkers at ICU admission in relationship to the 24 h entire 
SOFA score (on the bottom). p < 0.0001 vs. plasma levels at ICU admission.
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Table 3: Independent determinants of levels of high-sensitivity 
C-reactive protein (hsCRP), pentraxin 3 (PTX3), and soluble suppres-
sion of tumorigenicity 2 (sST2), at ICU admission (0 h) and 48 h later.
Biomarker Variable β p-Value
hsCRP, 0 h Age 0.007 0.308
Sex (male) –0.215 0.373
Shockable rhythm –0.738 0.001
Bystander CPR –0.279 0.166
Adrenaline 0.484 0.043
Time to ROSC –0.020 0.048
PTX3, 0 h Age 0.011 0.052
Sex (male) –0.004 0.982
Shockable rhythm –0.159 0.356
Bystander CPR 0.044 0.788
Adrenaline 0.521 0.008
Time to ROSC 0.011 0.177
SST2, 0 h Age 0.003 0.490
Sex (male) –0.179 0.220
Shockable rhythm –0.455 0.000
Bystander CPR –0.116 0.339
Adrenaline 0.428 0.003
Time to ROSC –0.001 0.848
hsCRP, 48 h Shockable rhythm 0.056 0.617
Bystander CPR –0.043 0.643
Adrenaline 0.197 0.061
Time to ROSC 0.003 0.513
Therapeutic hypothermia 0.281 0.022
Apache II score 0.010 0.089
PTX3, 48 h Shockable rhythm 0.604 0.004
Bystander CPR 0.194 0.257
Adrenaline 0.129 0.508
Time to ROSC 0.003 0.709
Therapeutic hypothermia 0.238 0.297
Apache II score 0.024 0.032
sST2, 48 h Shockable rhythm –0.408 0.0009
Bystander CPR –0.016 0.867
Adrenaline 0.246 0.032
Time to ROSC 0.009 0.101
Therapeutic hypothermia 0.357 0.008
Apache II score 0.029  < 0.0001
Multivariable linear regression model.
Inflammatory markers at ICU admission and 
MODS
At ICU admission, plasma levels of PTX3 and sST2 were 
significantly higher in patients with higher 24  h SOFA 
scores (Figure 1). Moreover, PTX3 and sST2 levels were 
significantly higher in patients who developed MODS 
compared to those who did not (Figure 2). The AUCs of the 
ROC curves for prediction of MODS were 0.78 (p < 0.0001) 
and 0.74 (p < 0.0001) for PTX3 and sST2 (p = 0.204 PTX3 vs. 
sST2), respectively (Figure 2). A plasma level of 24 ng/mL 
of PTX3 had a sensitivity of 0.8 and a specificity of 0.7 to 
predict development of MODS. Similarly, a plasma level of 
141 ng/mL of sST2 had a sensitivity of 0.8 and a specificity 
of 0.7 to predict development of MODS (Figure 2).
Plasma levels of hsCRP were also significantly higher 
in patients who developed MODS compared to those who 
did not, but with a lower accuracy (AUC of 0.6, p = 0.033) 
compared to PTX3 (p < 0.003) and sST2 (p < 0.014). The uni-
variate odds ratios for prediction of MODS were: 1.922 (95% 
CI 1.351–2.736, per 1 SD, p = 0.0003) for PTX3; 1.565 (1.181–
2.074, per 1 SD increase, p = 0.0003) for sST2; and 1.316 (95% 
CI 1.004–1.724, per 1 SD increase, p = 0.0466) for hsCRP. 
Plasma levels of PTX3 and sST2, but not hsCRP, were also 
independently associated with development of MODS in 
the multivariable analysis: OR 1.717 (95% CI 1.221–2.414, per 
1 SD, p = 0.0019) for PTX 3; OR 1.340 (95% CI 1.001–1.792, per 
1 SD, p = 0.048), respectively) for sST2; and OR 1.115 (95% CI 
0.833–1.491, per 1 SD increase, p = 0.464) for hsCRP.
Inflammatory markers and ICU survival
Plasma levels of PTX3 and sST2 at ICU admission and 
levels of hsCRP and sST2 48  h later were significantly 
higher in patients who died compared to those who sur-
vived at ICU discharge (Figure 3). The odds ratios for pre-
diction of ICU mortality of these inflammatory markers 
are detailed in Table 4.
In a multivariable model, including the initial cardiac 
arrest rhythm (shockable or non-shockable), time to ROSC, 
use of adrenaline, and whether therapeutic hypothermia 
was applied or not (Table 1), plasma levels of PTX3 and 
sST2 at ICU admission and of sST2 and hsCRP 48 h later 
were independently associated with ICU death (Table 4).
The AUCs of the ROC curves for prediction of ICU death 
were 0.71 (p < 0.0001) for PTX3 at ICU admission (p = 0.078 
vs. sST2 and p = 0.005 vs. hsCRP), 0.78 (p < 0.0001) and 
0.72 (p < 0.0001) for sST2 (p = 0.008 vs. PTX3 and p = 0.417 
vs. hsCRP) and hsCRP (p = 0.175 vs. PTX3), respectively, at 
48  h after ICU admission (Figure 4). The optimal cut-off 
levels for prediction of ICU death were: 24 ng/mL for PTX3 
at ICU admission (sensitivity of 0.7 and a specificity of 
0.7); 604 ng/mL for sST2 (sensitivity of 0.6 and a specific-
ity of 0.9) and 145 mg/L for hsCRP at 48 h (sensitivity of 0.7 
and a specificity of 0.7) (Figure 4).
Inflammatory markers and 12-month 
 unfavorable outcome
Plasma levels of PTX3 and sST2 at ICU admission and of 
sST2 48  h later were significantly higher in patients who 
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had a unfavorable outcome at 12 months compared to those 
who had a good recovery (Figure 5). However, in the multi-
variable model, none of the studied biomarkers was inde-
pendently associated with 12-month unfavorable outcome 
(Table 4). The odds ratios for prediction of 12-month 
unfavorable outcome of these inflammatory markers at ICU 
admission and 48 h later are detailed in Table 4.
Discussion
The present study showed that plasma levels of PTX3 
and sST2 were markedly elevated early after resuscitation 
from out-of-hospital cardiac arrest. Higher plasma levels 
of PTX3 and sST2 at ICU admission were associated with 
higher 24  h SOFA score and with development of MODS 
and were independently associated with death in ICU. In 
contrast, hsCRP increased later compared to PTX3 and 
sST2, so that only 48  h levels were associated with ICU 
outcome. Plasma levels of PTX3 and sST2 at ICU admis-
sion were also significantly higher in patients with an 
unfavorable 12-month outcome compared to those with a 
favorable outcome, although they were not independently 
associated with it in the multivariable model.
PTX3 is a prototypic long pentraxin, component of the 
humoral arm of innate immunity that can regulate inflam-
matory processes. It shares similarities with CRP, a pro-
totypic short pentraxin, but differs in terms of structural 
domains, gene organization, cellular and tissue sources, 
inducing stimuli, and ligands [13]. Indeed, PTX3 is pro-
duced mainly by myeloid cells and vascular endothelial 
cells in response to primary inflammatory stimuli [7, 13, 
21, 22]. In addition the protein is stored by neutrophils in 
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Table 4: Univariate and multivariable logistic regression models for prediction of ICU death, and 12-month unfavorable outcome.
Univariate Multivariable
OR 95% CI p-Value OR 95% CI p-Value
ICU death
 hsCRP, 0 h 1.342 1.027–1.754 0.031 1.056 0.778–1.432 0.728
 hsCRP, 48 h 2.091 1.374–3.182 0.0006 1.986 1.263–3.123 0.003
 PTX3, 0 h 1.763 1.274–2.439 0.0006 1.536 1.078–2.187 0.0174
 PTX3, 48 h 1.247 0.931–1.762 0.139 1.230 0.896–1.688 0.201
 sST2, 0 h 1.820 1.331–2.488 0.0002 1.452 1.064–1.981 0.019
 sST2, 48 h 2.151 1.539–3.006  < 0.0001 1.856 1.272–2.707 0.0013
12-month unfavorable outcome
 hsCRP, 0 h 1.488 1.053–2.101 0.024 1.073 0.741–1.552 0.710
 hsCRP, 48 h 1.105 0.849–1.439 0.457 0.883 0.642–1.214 0.444
 PTX3, 0 h 1.618 1.073–2.440 0.022 1.183 0.813–1.723 0.380
 PTX3, 48 h 1.398 0.899–2.173 0.137 1.229 0.775–1.950 0.381
 sST2, 0 h 1.888 1.235–2.884 0.003 1.303 0.873 –1.946 0.196
 sST2, 48 h 1.896 1.329–2.704 0.0004 1.318 0.910–1.907 0.144
hsCRP, high-sensitivity C-reactive protein; OR, odds ratio per 1 SD increase; PTX3, pentraxin 3; sST2, soluble suppression of tumorigenicity 2.
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Figure 4: Receiver operator curves (ROC) and area under the curves (AUC) for plasma levels of high-sensitivity C-reactive protein (hsCRP), 
pentraxin 3 (PTX3), and soluble suppression of tumorigenicity 2 (sST2) at ICU admission (0 h) and 48 h for prediction of ICU death.
p = 0.078 at ICU admission and p = 0.008 at 48 h for AUC PTX3 vs. AUC sST2; p = 0.005 at ICU admission and p = 0.175 at 48 h for AUC PTX3 vs. 
AUC hsCRP; p = 0.035 at ICU admission and p = 0.417 at 48 h for AUC sST2 vs. AUC hsCRP.
specific granules and is promptly released in response to 
tissue damage [23]. Thus, in contrast to CRP that is primary 
synthesized in the liver and thereby reflects systemic 
inflammation, PTX3 is, at least in part, synthesized at 
the site of inflammation [21], behaving as an acute phase 
response protein that increases rapidly and peaks within 
6–8 h after the insult [24]. In the instance of cardiac arrest, 
as early as 3  h after resuscitation, blood concentrations 
of soluble intercellular adhesion molecule-1, soluble 
vascular-cell adhesion molecule-1, and P- and E-selectins 
increase, suggesting leucocyte and endothelial activation, 
which together with the protein released by neutrophils, 
account for rapid PTX3 release [2, 23, 25, 26]. In our study, 
the median PTX3 levels at ICU admission were, in fact, 
already 10-fold higher compared to normal values, in con-
trast to normal levels of hsCRP.
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We have previously reported that PTX3, compared 
with other biomarkers considered reliable predictors of 
mortality in acute cardiovascular events, i.e., natriuretic 
peptides and cardiac troponins, appeared as an earlier 
and stronger predictor of worsening of heart failure and 
death in patients with ST-elevation myocardial infarction 
as well as in patients with chronic heart failure [7, 20, 27]. 
Moreover, high plasma levels of PTX3 have also emerged 
as prognostic markers for severe sepsis and septic shock, 
with a gradient from systemic inflammatory response syn-
drome to septic shock [8, 28]. In our study, PTX3 has now 
emerged as a useful biomarker predictive of the severity of 
post-resuscitation syndrome and early death after cardiac 
arrest. Patients with a median value of PTX3  > 24 ng/mL 
at ICU admission had a 92% higher risk of developing 
MODS, and a 54% higher risk of dying in ICU, compared to 
patients with lower values.
PTX3 is a multifunctional protein with in vivo roles 
that remain in part controversial [22]. In fact, PTX3 was 
known to bind C1q with consequent activation of the 
classic pathway of the complement when bound to immo-
bilized ligands [29]. Therefore, locally produced PTX3 
was recognized to cause and amplify tissue damage [7]. 
Moreover, PTX3 was also known to inhibit angiogenesis 
and tissue repair, by binding and inactivation of fibro-
blast growth factor [30]. Recent observations, however, 
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Figure 5: Plasma levels of high-sensitivity C-reactive protein 
(hsCRP), pentraxin 3 (PTX3), and soluble suppression of tumori-
genicity 2 (sST2) at ICU admission (0 h) and 48 h and long-term 
neurological outcome based on Cerebral Performance Category (CPC 
1–2, favorable and CPC 3–5, unfavorable).
**p < 0.01 vs. favorable outcome.
support the possibility that PTX3 may act as a molecule at 
the crossway between pro- and anti-inflammatory stimuli, 
regulating leukocyte recruitment and perhaps balancing 
the over activation of pro-inflammatory cascades [31, 
32]. Indeed, it has been shown that fluid-phase PTX3 can 
sequester C1q and prevent complement activation [33]. 
Thus, PTX3 may exert a dual role and contrasting effects 
on complement activation in ischemia/reperfusion [7, 32]. 
PTX3-deficient mice, in fact, had increased C3 deposition 
and amplified tissue damage in the ischemic myocardium, 
while administration of exogenous PTX3 reduced such a 
complement deposition exacerbated damage after reper-
fusion [32]. Therefore, the high level of circulating PTX3 
in our patients may be considered as both an indicator of 
the severity of post-ROSC inflammation, as well as one of 
the pathophysiological players in the post-cardiac arrest 
syndrome, thus explaining its association with death.
ST2 is a protein of the IL-1 receptor family that binds 
IL-33. Its homology with the toll-like receptor and other 
IL-1 family members suggests that it may play a central 
role in innate and adaptive immune responses [9, 10]. As 
suggested for PTX3, in cardiac arrest patients, sST2 may 
be, therefore, not only a marker/indicator of the severity 
of the post-ROSC inflammatory status, but it may also be 
directly involved in its pathophysiology. Indeed, earlier 
investigations have revealed sST2 participation in the 
regulation of inflammatory processes, particularly regard-
ing mast cells, type 2 CD4+ T-helper (Th) cells and the 
production of Th2-associated cytokines [9, 10]. Although 
sST2 gene is markedly induced in the instance of mechani-
cally overloaded cardiac myocytes, i.e., during acute and 
chronic heart failure, ST2 seems to be produced also in 
response to inflammatory stimuli [34, 35]. Circulating ST2 
levels have never been reported in cardiac arrest. Thus, 
of interest were the levels of sST2 in our patients, 117 ng/
mL at ICU admission and 276 ng/mL 48 h later, that were 
2–4-fold greater than those reported in acute heart failure 
patients [36]. The initial sST2 increase might have been 
related to the post-cardiac arrest systemic inflammation, 
while the further increase to the overloaded myocardial 
cells within the condition of severe post-resuscitation 
myocardial dysfunction [1].
In over 800 patients with an acute ST-elevation 
myocardial infarction, levels of sST2 at hospital admis-
sion were significantly higher in those who died or 
developed heart failure [10]. Similarly, in large cohorts 
of patients with acute heart failure, sST2 was associated 
with a more decompensated hemodynamic profile with 
left and right ventricular dysfunction, and with higher 
risk of hospitalization and death [11, 36–38]. Moreover, 
levels of circulating sST2 were elevated also in patients 
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admitted to ICU with a diagnosis of sepsis or after severe 
trauma [12]. Similarly to PTX3, in our study, sST2 has 
emerged as another useful biomarker predictive of the 
severity of post-resuscitation syndrome and early death. 
Patients with a median value of sST2  > 142 ng/mL at ICU 
admission had a 57% higher risk of developing MODS, 
and a 45% higher risk of dying in ICU, compared to 
patients with lower values. Association with early death 
remained, although with a reduced sensitivity, for sST2 
levels at 48 h, with an 86% increased relative risk when 
values were above 600 ng/mL.
Role of CRP after cardiac arrest is controversial. 
Indeed, several studies in small cohorts of patients have 
described important post-resuscitation increases in CRP, 
peaking in 48–72 h independently from infection [39]. A 
significant correlation between peak CRP levels, cardio-
vascular dysfunction, and SOFA score has been reported, 
together with association with death and poor neuro-
logical outcome [39–41]. Other studies, however, have 
reported no correlation between CRP levels and severity 
of post-cardiac arrest syndrome or outcome [4, 42]. Our 
study further confirmed the weak association of admis-
sion levels of hsCRP with the severity of post-resuscitation 
syndrome and no association with ICU survival. Neverthe-
less, high hsCRP levels at 48  h after resuscitation were 
independently associated with ICU death.
In agreement with previous reports, inflammatory 
markers levels in our study were higher in patients with 
non-shockable rhythm, with longer time to ROSC, and 
that received adrenaline during CPR [41]. As previously 
suggested, because non-shockable rhythms are usually 
associated with other pathological conditions, the high 
levels of our markers may reflect the presence of a general 
inflammatory status that preceded and/or led to cardiac 
arrest [41]. Moreover, a longer duration of cardiac arrest, 
including both no-flow and low-flow times, and the use 
of adrenaline, are known to be associated with a greater 
severity of post-cardiac arrest syndrome, and plausibly 
accounted for the higher levels of inflammatory markers 
[1, 43]. Finally, at 48  h post-ROSC, patients treated with 
hypothermia presented significantly higher levels of 
hsCRP and sST2, similar to earlier investigations [4]. The 
continuous rising of inflammatory markers after hypo-
thermia has been explained as a consequence of the 
endothelial activation that declines during cooling while 
it increases again following rewarming [4, 5].
We acknowledge several limitations in the interpreta-
tion of our findings. First, this was a biomarker substudy 
of the FINNRESUSCI trial. Nevertheless, all the patients 
with a blood sample were included in the study and the 
biomarker analyses, data collection, outcome evaluation 
and statistics were performed independently. Second, we 
did not report data on cardiac disease or other comorbidi-
ties. Indeed, all the biomarkers are associated with cardio-
vascular risk so it is possible that their levels on admission 
might have been influenced by the presence of a pre-exist-
ing cardiac disease [44].
In conclusion, after cardiac arrest, the temporal 
release patterns of the inflammatory markers PTX3, sST2, 
and hsCRP showed large differences with an early cellular 
and vascular response, leading to PTX3 and sST2 release, 
whereas the organ derived inflammatory marker hsCRP 
was released more slowly. Thus, ICU admission levels of 
PTX3 and sST2 are independent predictors of MODS and 
early death after cardiac arrest, while CRP is not. Never-
theless, PTX3, sST2 and hsCRP levels continued to rise at 
48 h after cardiac arrest, suggesting that systemic activa-
tion of the pro-inflammatory response is prolonged and 
could be therefore a potential target for intervention.
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